Metastasis of renal cell carcinoma to the urethra: a rare scenario

Sofia Frade Santos 1, Pedro Oliveira Santos 1, Delfim Doutel 1, José Venâncio 1

1 Instituto Português de Oncologia de Lisboa Francisco Gentil – IPOLFG, Lisboa, Portugal

INTRODUCTION

Urethral metastasis from renal cell carcinoma is extremely rare, especially in the absence of other metastatic sites. We present a case of a urethral solitary lesion corresponding to metastasis of a previously diagnosed clear cell renal cell carcinoma.

CASES PRESENTATION

We report the case of a 67-year-old man with an acute episode of gross hematuria with no reported trauma, fever, dysuria, or flank pain. Six months before admission the patient underwent radical left nephrectomy for clear cell renal cell carcinoma (RCC) (Figure-1A). On histological analysis, the tumor invaded the perinephric fat without signs of vascular invasion nor renal sinus invasion. The surgical margins were free of tumor.

The patient’s past medical history was also remarkable for chronic renal failure caused by polycystic kidney disease. A cystourethroscopy revealed a polypoid lesion in the bulbous urethra, along an approximate length of 3cm. It was resected endoscopically and pathological analysis (Figure-1B) confirmed infiltration by carcinoma morphologically similar to the previously resected renal tumor.

He was readmitted two months after endoscopic resection with recurrent hematuria and, subsequently, an acute urinary retention episode. A urinary catheter was placed after some technical difficulties and a hemorrhage.

A computed tomography (CT) (Figure 1-C) showed early enhancement after contrast injection along the penile bulb and proximal body of the penis.

Magnetic resonance imaging (MRI) demonstrated an area of marked T2 heterogeneity (Figures 2A and B) involving the bulb and proximal body of the penis with heterogeneous contrast enhancement after gadolinium injection and restrictive on diffusion-weighted imaging (DWI). There was a loss of the regular anatomic planes between the urethra and the surrounding corpus spongiosum.

These findings were suspicious for regrowth of the metastatic lesion. There were no other suspected metastases.

The patient was considered not eligible for surgery, therefore therapy with sunitinib was initiated. This treatment was temporarily interrupted due to toxicity manifested as asthenia, thrombocytopenia, and cardiotoxicity.

After three therapeutic cycles, there was no recurrence of haematuria nor the development of significant lower urinary tract symptoms. The follow-up MRI (Figures 2C and D) showed a reduction in the lesion’s extension. The morphological MRI sequences, namely T2-weighted images (T2WI), also confirmed less heterogeneity with a better definition of the anatomical planes. Unequivocal restricted diffusion was no longer evident.
Renal cell carcinoma (RCC) is the most common primary renal malignancy, with clear cell RCC being the most frequent histological subtype (1).

The lung, bone, liver, and adrenal gland are common metastatic sites of RCC (1, 2). The urethra is one of the infrequent metastatic sites. To our knowledge, there are only eight cases reported in the literature (3-10), mostly in male patients. Only some represent solitary metastases. In our case, the first metastatic site was the bulbous urethra.

Urethral metastases from other primary sites are also rare, although they are more common than primary urethral tumors (11). The length of the urethra is much larger in men than in women, and that fact may explain the higher rates of urethral metastases in male patients (10). MRI is considered the imaging modality of choice in the assessment of secondary urethral tumors to depict the location, size, and local extension due to proper soft-tissue resolution (11). Extensive secondary tumoral involvement of the urethra presents as a solid nodular or cylindrical mass with heterogeneous contrast enhancement (11), as in our case.
During follow-up imaging (CT and MRI), the recurrence of the histologically proved metastatic lesion was suspected. Clinical and imaging data showed a favourable response to sunitinib, a tyrosine kinase inhibitor used in the treatment of metastatic RCC (12-14).

The lesion reported on MRI (Figure-2A-B) caused the loss of the anatomical planes between the urethra and corpus spongiosum. Probably, it is explained by direct extension of the known urethral metastasis to the surrounding corpus spongiosum. The penis is a rare site of metastases and usually affects the corpora cavernosa, while corpus spongiosum invasion is rare (15, 16). Most penile metastatic lesions are associated with disseminated metastatic disease and carry an overall poor prognosis (15, 17). Urethral and penile metastases may be explained by hematogenous, instrumental and, retrograde lymphatic spread. Dissemination through the urinary excretory system or even direct extension should also be considered (10, 11). Spread of tumor cells through the distal urinary excretory system may be favored by the location of a primary tumor in the kidney (close to the renal collecting system) (10).

Infrequent sites of metastatic disease may delay its detection (1), as illustrated by our case. In patients with a known primary malignancy, a metastatic deposit, although rare, should be considered as a cause for the development of lower urinary tract symptoms.

Figure 2 (A-D) – MRI of the urethral metastasis (T2WI). Axial (A) and sagittal (B) images show an area of marked T2 heterogeneity involving the bulb (white arrow in A) and proximal body of the penis (black arrow in B) with a gross cylindrical shape. This lesion has an estimated total extension of 10 cm. It is presumably centred in the urethra (penile, bulbous and membranous) with loss of the normal anatomic planes between the urethra and the surrounding corpus spongiosum. The described lesion corresponds to an area with heterogeneous contrast enhancement after gadolinium injection and restricted diffusion (not shown). Followup MRI of the pelvis after three therapeutic cycles with sunitinib revealed a reduction of the lesion’s extension and less heterogeneity, with a better definition of the anatomical planes (C and D). There was no significant restriction to diffusion on DWI (not shown).
ABBREVIATIONS

RCC = renal cell carcinoma;
CT = computed tomography;
MRI = magnetic resonance imaging;
DWI = diffusion-weighted imaging;
T2WI = T2-weighted images

REFERENCES

1. Diaz de Leon A, Pirasteh A, Costa DN, Kapur P, Hammers H, Brugarolas J, et al. Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma. Radiographics. 2019; 39:998-1016.
2. Griffin N, Gore ME, Sohaib SA. Imaging in metastatic renal cell carcinoma. AJR Am J Roentgenol. 2007; 189:360-70.
3. Goldberg MG, Plaine L. Solitary metastasis of renal cell carcinoma to urethra. Urology. 1990; 35:351-3.
4. Fukata S, Inoue K, Moriki T, Shuin T. A solitary metastasis of renal cell carcinoma to the urethra. J Urol. 2000; 163:1245-6.
5. Senzaki H, Okamura T, Tatsura H, Watase H. Urethral metastasis from renal cell carcinoma. Int J Urol. 2003; 10:661-3.
6. Cheng CW, Wong WS, Chan LW, Lai FM. A rare cause of acute urinary retention: urethral metastasis from renal cell carcinoma. Int Urol Nephrol. 2004; 36:145-7.
7. Bailie J, Wood E, Connolly D, O’Rourke D. Urethral metastasis from renal cell carcinoma: An unusual cause of visible painless haematuria. J Clin Urol.2012, 6:188-90.
8. Kravvas G, Varnavas M, Aldujaily S. A unique presentation of an undiagnosed renal cell carcinoma. Case Rep Urol. 2014;2014:840163.
9. Pirola GM, Martorana E, Fidanza FA, Bonetti LR, Pulitii S, Bonora A, et al. Rare metastatic sites of renal cell carcinoma: urethra and spermatic cord. Urologia. 2016; 83:214-7.
10. Gawlik-Jakubczak T, Matuszewski M, Biernat W. The Metastasis of Renal Cell Carcinoma to the Urethra and Local Tumor Recurrence. Urol Int. 2020; 104:327-9.
11. Karioosmanoglu AD, Onur MR, Karcaaltincaba M, Akata D, Ozmen MN. Secondary Tumors of the Urinary System: An Imaging Conundrum. Korean J Radiol. 2018; 19:742-51.
12. Rizzo M, Porta C. Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. Ther Adv Urol. 2017; 9:195-207.
13. Toussi A, Agarwal D, Leibovich B, Potretzke A. Percutaneous resection of metastatic renal cell carcinoma. Int Braz J Urol. 2019; 45:640.
14. Wang B, Gu W, Wan F, Shi G, Ye D. Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma. Int Braz J Urol. 2019; 45:89-99.
15. Meairini L, Colella R, Zucchi A, Nunzi E, Porrozzi C, Porena M. A review of penile metastasis. Oncol Rev. 2012; 6:e10.
16. Nezu FM, Dhir R, Logan TF, Lavelle J, Becich MJ, Chancellor MB. Malignant priapism as the initial clinical manifestation of metastatic renal cell carcinoma with invasion of both corpora cavernosum and spongiosum. Int J Impot Res. 1998;10:101.
17. Romero Selas E, Lamas Meilán C, Barbagelata López A, Ponce Díaz-Reixa JL, Fernández Rosado E, Alvarez Castelo L, et al. Metastasis de carcinoma renal en cuerpo cavernoso, a propósito de un caso y revisión de la literatura [Metastasis of a renal cell carcinoma in the corpora cavernosum of the penis. Case report and bibliographic review]. Arch Esp Urol. 2006;59:530-2. Spanish.

CONFLICT OF INTEREST

None declared.

ARTICLE INFO

Sofia Frade Santos, MD
Radiology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil
Rua: Professor Lima Basto, 1099-023
Lisboa, Portugal
Telephone: + 351 21 722-9800
E-mail: sfsantos@ipolisboa.min-saude.pt

https://orcid.org/0000-0001-8609-2265

Int Braz J Urol. 2021; 47: 674-7

Submitted for publication: August 09, 2020
Accepted after revision: September 29, 2020
Published as Ahead of Print: December 20, 2020